The DOI matches its Crossref record.
Early- and Long-Term Outcome Data of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Open accessAbstract
Purpose: Pseudomyxoma peritonei (PMP) originating from an appendiceal mucinous neoplasm remains a biologically heterogeneous disease. The purpose of our study was to evaluate outcome and long-term survival after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) consolidated through an international registry study. Patients and Methods: A retrospective multi-institutional registry was established through collaborative efforts of participating units affiliated with the Peritoneal Surface Oncology Group International. Results: Two thousand two hundred ninety-eight patients from 16 specialized units underwent CRS for PMP. Treatment-related mortality was 2% and major operative complications occurred in 24% of patients. The median survival rate was 196 months (16.3 years) and the median progression-free survival rate was 98 months (8.2 years), with 10- and 15-year survival rates of 63% and 59%, respectively. Multivariate analysis identified prior chemotherapy treatment (P < .001), peritoneal mucinous carcinomatosis (PMCA) histopathologic subtype (P < .001), major postoperative complications (P = .008), high peritoneal cancer index (P = .013), debulking surgery (completeness of cytoreduction [CCR], 2 or 3; P < .001), and not using HIPEC (P = .030) as independent predictors for a poorer progression-free survival. Older age (P = .006), major postoperative complications (P < .001), debulking surgery (CCR 2 or 3; P < .001), prior chemotherapy treatment (P = .001), and PMCA histopathologic subtype (P < .001) were independent predictors of a poorer overall survival. Conclusion: The combined modality strategy for PMP may be performed safely with acceptable morbidity and mortality in a specialized unit setting with 63% of patients surviving beyond 10 years. Minimizing nondefinitive operative and systemic chemotherapy treatments before definitive cytoreduction may facilitate the feasibility and improve the outcome of this therapy to achieve long-term survival. Optimal cytoreduction achieves the best outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Coccolini, F. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i41.6979 · Cited by 325
Roberts, D. L., O’Dwyer, S. T., Stern, P. L., & Renehan, A. G. (2015) · Oncotarget · doi:10.18632/oncotarget.3198 · Cited by 42
Baumgartner, J. M., Riviere, P., Lanman, R. B., Kelly, K. J., Veerapong, J., Lowy, A. M., & Kurzrock, R. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08331-x · Cited by 25
Metadata
- Authors
- Chua, T. C., Moran, B. J., Sugarbaker, P. H., Levine, E. A., Glehen, O., Gilly, F. N., Baratti, D., Deraco, M., Elias, D., Sardi, A., Liauw, W., Yan, T. D., Barrios, P., Gómez Portilla, A., de Hingh, I. H. J. T., Ceelen, W. P., Pelz, J. O., Piso, P., González-Moreno, S., Van Der Speeten, K., & Morris, D. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-07-10
- Volume
- 30
- Issue
- 20
- Pages
- 2449-2456
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2097198751
- Cited by
- 1,071
- References
- 0
- FWCI
- 59.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early- and Long-Term Outcome Data of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. https://app.cochat.ai/papers/10.1200/jco.2011.39.7166
- The paper
- Chua, T. C., Moran, B. J., Sugarbaker, P. H., Levine, E. A., Glehen, O., Gilly, F. N., Baratti, D., Deraco, M., Elias, D., Sardi, A., Liauw, W., Yan, T. D., Barrios, P., Gómez Portilla, A., de Hingh, I. H. J. T., Ceelen, W. P., Pelz, J. O., Piso, P., González-Moreno, S., . . . Morris, D. L. (2012). Early- and Long-Term Outcome Data of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.39.7166
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
